Samenvatting

Samenvatting preclinical drug research (17/20)

4 keer verkocht

Vak
Preclinical drug research

Instelling
Universiteit Antwerpen (UA)

Full summary of the subject 'Preclinical drug research taught by prof. Van Cruchten & prof. Delputte. Both the general lessons as the guest lessons 'biopharmaceuticals' are included in this summary.

[Meer zien]

Voorbeeld 4 van de 64 pagina's

Bekijk voorbeeld

Geupload op 20 februari 2024
Aantal pagina's 64
Geschreven in 2023/2024
Type Samenvatting

Volgen

nikitacassimon Lid sinds 11 maanden 23 documenten verkocht

€15,99

In winkelwagen

Op verlanglijstje

100% tevredenheidsgarantie
Direct beschikbaar na je betaling
Lees online óf als PDF
Geen vaste maandelijkse kosten

Nikita Cassimon 2e master geneesmiddelenontwikkeling: biofarmaceutische wetenschappen

Preclinical Drug Research
Introduction:

Molecule Drug
Up to 12 years
Costly
Depends on target population and market

Small molecules
• SMI = Small Molecular Entities Ex. aspirin, fluoxetine,
Chemicals
• Oral administration omeprazole
• For many diseases not a solution
Complex molecules Ex. artemether, paclitaxel,
Natural products
vinblastine
Large (complex) molecules
• Also: New Therapeutic Modalities =
Biologicals biopharmaceuticals + gene therapy Ex. insulin, interferon, EPO
included
• Parenteral administration

Drug R&D spending in different industry sectors & therapeutic areas:

• Biggest cost for • Spendings in • Smaller countries, smaller
biopharmaceuticals pharmaceutical companies expenses
because of small target increase • Cost of bringing a new SMI
population • Not many drugs are or biological to the market
• Ex. 200k euros for 1 approved → if approved it keeps increasing over the
administration in 1 patient needs to compensate for al years
the expenses and failures
• ‘Fail fast Fail cheap’

Major disease areas:

1. Cardiovascular diseases
2. Neoplasm (cancer)
• 3. Respiratory system diseases
• 4. Digestive system diseases
5. CNS diseases

,Nikita Cassimon 2e master geneesmiddelenontwikkeling: biofarmaceutische wetenschappen

R&D spending & therapeutic areas:

• Biggest investment: clinical trials → facilities in the world and amount of patients
• Need for a nonclinical package depends on the patients
• Phase I CT: healty young males people → no women: potential fertilty danger + abortion →
recovery spermatogenesis after a few months
• Conclusion: risk in men is lower + smaller clinical package (less data needed)

Other factors:

Annual population growth Healthcare spending in relation Pharmaceutical sales by
rates: to age: region:
• Ideal: lot of target patients • Diseases/treatments • Most sales: USA → a lot of
• China: boost of pharma increase with ages OTC in supermarkets
companies → competition • You don’t want: adverse • Emerging: China
• Latin America: less effects → • Established ROW: India,
investment subtherapeutic dose Brazil
• Africa: increasing trend • = RISK/BENEFIT-ratio

Total cost for one new marketed drug = about 0.8 – 1.5 billion USD (depends on therapeutic area)

Orphan diseases = diseases occuring in a low amount of patients → definition depends on the place
and amount of patients (< 1000)

• Pharmaceutical companies don’t make profit with the development or drugs → you can make
profit if you’re ‘first-in-class’
• Investment by the Bill Gates foundation
• Some bigger companies tactically buy smaller companies to make profit

Compensate
investment by
making profit after
Decrease of profit
launching the drug
after expiring
patent + generic
competition
Investment in clinial
development → no
profit is made here

, Nikita Cassimon 2e master geneesmiddelenontwikkeling: biofarmaceutische wetenschappen

Blockbuster drug = a drug with sales > 1 billion USD/year

• Ex. Humira: 20 USD/year
• Blockbuster drugs moslty come from bigger companies, because they can afford a big investment
• Detectives visit smaller companies and detect drugs with potential,bigger companies later buy
them or steal the idea and license it

Top launches 2019: Patents: Competition in pharmaceutical
• Increase of • Patent will expire after 20 market:
biopharmaceuticals years, but 12 years are • Most profit fort he ‘first-in-
• Nonclinical package needed to develop drug → class’ developper
specialized for monoclonal profit for 8 years • Shrinking period of market
AB • SPC = supplementary exclusivity
• Gene therapy → protection certificate → • Inceased competition
companies decide what max. +5 years extra between pharmaceutical
refund the patient will get patented companies
Ex. Zolgensma • Me-too drugs = drugs die
op elkaar lijken

• Generics: high volume, high level of
competition, low value product, low medical
differentiation
• Mega-blockbusters: everything medium
• Targeted therapeutics: low volume, low level
of competition, high product value, high
medical differentiation

Failure rates in drug development:

‘Fail Fast Fail Cheap’

Phase I: No adverse
effects in young healthy
men

Approved: post-marketting
Phase II: Lack of efficacy issues → impact on image
on bigger scale of company

, Nikita Cassimon 2e master geneesmiddelenontwikkeling: biofarmaceutische wetenschappen

Biotechnology-derived medicines:

• Oligonucleotides working on mRNA
• Small interfering RNAs Larger proportion of
• Micro RNAs ‘first-in-class’
• Vaccines therapeutics
• Monoclonal antibodies

Ex. In 1982: Recombinant human insulin or Humulin®

Major pharmaceutical companies (from biggest to smallest):

• Locations: 150 countries • Locations: > 140 countries and > 100,000
• Headquarter: Basel, Switzerland employees
• Diagnostics • Headquarter: Basel, Switzerland
• Sandoz for generics

• Locations: > 150 countries • Locations: 120 countries
• Headquarter: New York, USA • Headquarter: Whitehouse Station, New
• Belgian sites: Puurs (no R&D but Jersey, USA
manufacturing)
• Offers a broadspectrum of drugs
• Drugs not approved for humans used for
animals

• Locations: > 55 countries • Locations: > 100 countries and > 100,000
• Headquarter: New Brunswick, New Jersey, employees
USA • Headquarter: Paris, France
• Beerse: R&D, pharmaceutical production • Ablynx is bought by Sanofi in 2018
(tablets, ointments, e.a.)
• Geel: chemical production (API)
• Olen: pharmaceutical production

• Locations: 117 countries • Locations: mainly Japan, but also
• Headquarter: UK Switzerland, USA, UK and Singapore
• OTC and toothpaste focused • Headquarter: Osaka, Japan

Dit zijn jouw voordelen als je samenvattingen koopt bij Stuvia:

Bewezen kwaliteit door reviews

Studenten hebben al meer dan 850.000 samenvattingen beoordeeld. Zo weet jij zeker dat je de beste keuze maakt!

In een paar klikken geregeld

Geen gedoe — betaal gewoon eenmalig met iDeal, Bancontact of creditcard en je bent klaar. Geen abonnement nodig.

Focus op de essentie

Studenten maken samenvattingen voor studenten. Dat betekent: actuele inhoud waar jij écht wat aan hebt. Geen overbodige details!

Veelgestelde vragen

Wat krijg ik als ik dit document koop?

Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.

Tevredenheidsgarantie: hoe werkt dat?

Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.

Van wie koop ik deze samenvatting?

Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper nikitacassimon. Stuvia faciliteert de betaling aan de verkoper.

Zit ik meteen vast aan een abonnement?

Nee, je koopt alleen deze samenvatting voor €15,99. Je zit daarna nergens aan vast.

Is Stuvia te vertrouwen?

4,6 sterren op Google & Trustpilot (+1000 reviews)

Afgelopen 30 dagen zijn er 68175 samenvattingen verkocht

Opgericht in 2010, al 15 jaar dé plek om samenvattingen te kopen

Start met verkopen

Samenvatting

Samenvatting preclinical drug research (17/20)

Document informatie

Onderwerpen

Geschreven voor

Verkoper

Ontvangen beoordelingen

Voorbeeld van de inhoud